File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin

TitleA randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin
Authors
KeywordsAmygdala
dose-frequency
fearful faces
oxytocin
oxytocin receptor gene
resting-state
Issue Date2022
Citation
Psychological Medicine, 2022, v. 52, n. 10, p. 1959-1968 How to Cite?
AbstractBackground The neuropeptide oxytocin is proposed as a promising therapy for social dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical trials report some benefits of chronic treatment, it is unclear whether efficacy may be influenced by dose frequency or genotype. Methods In a randomized, double-blind, placebo-controlled pharmaco-functional magnetic resonance imaging trial (150 male subjects), we investigated acute and different chronic (every day or on alternate days for 5 days) intranasal oxytocin (24 international units) effects and oxytocin receptor genotype-mediated treatment sensitivity on amygdala responses to face emotions. We also investigated similar effects on resting-state functional connectivity between the amygdala and prefrontal cortex. Results A single dose of oxytocin-reduced amygdala responses to all face emotions but for threatening (fear and anger) and happy faces, this effect was abolished after daily doses for 5 days but maintained by doses given every other day. The latter dose regime also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects on reducing amygdala responses to face emotions only occurred in AA homozygotes of rs53576 and A carriers of rs2254298. The effects of oxytocin on resting-state functional connectivity were not influenced by either dose-frequency or receptor genotype. Conclusions Infrequent chronic oxytocin administration may be therapeutically most efficient and its anxiolytic neural and behavioral actions are highly genotype-dependent in males.
Persistent Identifierhttp://hdl.handle.net/10722/330681
ISSN
2023 Impact Factor: 5.9
2023 SCImago Journal Rankings: 2.768
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKou, Juan-
dc.contributor.authorZhang, Yingying-
dc.contributor.authorZhou, Feng-
dc.contributor.authorSindermann, Cornelia-
dc.contributor.authorMontag, Christian-
dc.contributor.authorBecker, Benjamin-
dc.contributor.authorKendrick, Keith M.-
dc.date.accessioned2023-09-05T12:13:09Z-
dc.date.available2023-09-05T12:13:09Z-
dc.date.issued2022-
dc.identifier.citationPsychological Medicine, 2022, v. 52, n. 10, p. 1959-1968-
dc.identifier.issn0033-2917-
dc.identifier.urihttp://hdl.handle.net/10722/330681-
dc.description.abstractBackground The neuropeptide oxytocin is proposed as a promising therapy for social dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical trials report some benefits of chronic treatment, it is unclear whether efficacy may be influenced by dose frequency or genotype. Methods In a randomized, double-blind, placebo-controlled pharmaco-functional magnetic resonance imaging trial (150 male subjects), we investigated acute and different chronic (every day or on alternate days for 5 days) intranasal oxytocin (24 international units) effects and oxytocin receptor genotype-mediated treatment sensitivity on amygdala responses to face emotions. We also investigated similar effects on resting-state functional connectivity between the amygdala and prefrontal cortex. Results A single dose of oxytocin-reduced amygdala responses to all face emotions but for threatening (fear and anger) and happy faces, this effect was abolished after daily doses for 5 days but maintained by doses given every other day. The latter dose regime also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects on reducing amygdala responses to face emotions only occurred in AA homozygotes of rs53576 and A carriers of rs2254298. The effects of oxytocin on resting-state functional connectivity were not influenced by either dose-frequency or receptor genotype. Conclusions Infrequent chronic oxytocin administration may be therapeutically most efficient and its anxiolytic neural and behavioral actions are highly genotype-dependent in males.-
dc.languageeng-
dc.relation.ispartofPsychological Medicine-
dc.subjectAmygdala-
dc.subjectdose-frequency-
dc.subjectfearful faces-
dc.subjectoxytocin-
dc.subjectoxytocin receptor gene-
dc.subjectresting-state-
dc.titleA randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1017/S0033291720003803-
dc.identifier.pmid33272333-
dc.identifier.scopuseid_2-s2.0-85097240955-
dc.identifier.volume52-
dc.identifier.issue10-
dc.identifier.spage1959-
dc.identifier.epage1968-
dc.identifier.eissn1469-8978-
dc.identifier.isiWOS:000832634900017-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats